Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 2 , Pages 167-182 , April 2010

Adverse effects of biologics used for treating IBD

References 

  1. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117(1):49–57
  2. Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121(2):255–260
  3. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009;15(9):1295–1301
  4. Colombel J, Sandborn WJ, Rutgeerts P, et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol. 2009;104(5):1170–1179
  5. Klein NC, Go CH, Cunha BA. Infections associated with steroid use. Infect Dis Clin North Am. 2001;15(2):423–432[viii]
  6. Rahier J, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis. 2009;3(2):47–91
  7. Viget N, Vernier-Massouille G, Salmon-Ceron D, et al. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut. 2008;57(4):549–558
  8. Gea-Banacloche JC, Weinberg GA. Monoclonal antibody therapeutics and risk for infection. Pediatr Infect Dis J. 2007;26(11):1049–1052
  9. Colombel J, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126(1):19–31
  10. Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther. 2009;29(3):286–297
  11. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4(5):621–630
  12. Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134(4):929–936
  13. Ljung T, Karlén P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm county. Gut. 2004;53(6):849–853
  14. Schneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009;30(3):253–264
  15. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58(4):501–508
  16. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–2285
  17. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(8):2368–2376
  18. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007;56(6):1754–1764
  19. Bakleh M, Tleyjeh I, Matteson EL, et al. Infectious complications of tumor necrosis factor-alpha antagonists. Int J Dermatol. 2005;44(6):443–448
  20. Burmester GR, Mease PJ, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009;68(12):1863–1869
  21. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3(3):148–155
  22. Bean AG, Roach DR, Briscoe H, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol. 1999;162(6):3504–3511
  23. Stenger S. Immunological control of tuberculosis: role of tumour necrosis factor and more. Ann Rheum Dis. 2005;64(Suppl. 4):iv24–iv28
  24. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–1104
  25. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194):1932–1939
  26. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum. 2009;60(7):1884–1894
  27. Wallis RS. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum. 2008;58(4):947–952
  28. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52(6):1766–1772
  29. Mow WS, Abreu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004;2(4):309–313
  30. Schoepfer AM, Flogerzi B, Fallegger S, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol. 2008;103(11):2799–2806
  31. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol. 2008;35(5):776–781
  32. Aberra FN. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Gastroenterology. 2009;136(4):1453–1455
  33. Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis. 2009;48(10):1429–1432
  34. Blackmore TK, Manning L, Taylor WJ, et al. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis. 2008;47(10):e83–e85
  35. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore). 2005;84(5):291–302
  36. Smith JG, Magee DM, Williams DM, et al. Tumor necrosis factor-alpha plays a role in host defense against Histoplasma capsulatum. J Infect Dis. 1990;162(6):1349–1353
  37. Kato K, Nakane A, Minagawa T, et al. Human tumor necrosis factor increases the resistance against Listeria infection in mice. Med Microbiol Immunol. 1989;178(6):337–346
  38. Tsiodras S, Samonis G, Boumpas DT, et al. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008;83(2):181–194
  39. Torre-Cisneros J, Del Castillo M, Castón JJ, et al. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. Rheumatology (Oxford). 2005;44(9):1132–1135
  40. Helbling D, Breitbach TH, Krause M. Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol. 2002;14(12):1393–1395
  41. Reijasse D, Le Pendeven C, Cosnes J, et al. Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy. Inflamm Bowel Dis. 2004;10(2):85–90
  42. Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol. 2008;159(6):1217–1228
  43. Shale MJ, Seow CH, Coffin CS, et al. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31(1):20–34
  44. Vauloup C, Krzysiek R, Greangeot-Keros L, et al. Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. Eur Cytokine Netw. 2006;17(4):290–293
  45. Valdez H, Lederman MM. Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev. 1997;187–228
  46. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354(9):924–933
  47. Ko HH, Bressler B. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease. Expert Rev Gastroenterol Hepatol. 2007;1(1):29–39
  48. Sandborn W, Rutgeerts P, Reinisch W, et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy [late breaking abstract]. Am J Gastroenterol. 2008;103(S1):436
  49. Lin MV, Pascua MF, Aberra F, et al. The use of immunosuppressive medications as risk factor for non-opportunistic infectious complications in patients with IBD. DDW. 2009;Poster Abstract W1130
  50. FDA . Information for Healthcare Professionals: tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174474.htm2009;
  51. REMICADE (infliximab) for IV injection. Prescribing information. Malvern, PA: Centocor; 2009;Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103772s5234lbl.pdf
  52. Ekström K, Hjalgrim H, Brandt L, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum. 2003;48(4):963–970
  53. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692–701
  54. Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis. 2009;68(5):648–653
  55. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56(5):1433–1439
  56. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005;54(5):617–622
  57. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121(5):1080–1087
  58. Henriksen M, Jahnsen J, Lygren I, et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol. 2007;42(5):602–610
  59. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54(2):237–241
  60. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54(8):1121–1125
  61. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tnf and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7(8):874–881
  62. SEER . Surveillance, epidemiology, and end results database. Available at[Accessed 21.07.09] http://seer.cancer.gov/
  63. Lichtenstein GR, Cohen RD, Feagan BG. Safety of infliximab and other Crohn's disease therapies-treat (TM) registry data with nearly 20,000 patient-years of follow-up. Gastroenterology. 2007;132:A178
  64. Mackey AC, Green L, Leptak C, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr. 2009;48(3):386–388
  65. Kotlyar D, Blonski W, Porter DL, et al. Hepatosplenic T-cell lymphoma (HSTCL) and inflammatory bowel disease (IBD): a rare complication after long-term thiopurine exposure: case report and systematic review of the literature. DDW. 2009;Poster Abstract S1133
  66. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526–535
  67. Lakatos P, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol. 2008;14(25):3937–3947
  68. Erichsen R, Jepsen P, Vilstrup H, et al. Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978-2003. Eur J Epidemiol. 2009;24(9):513–520
  69. Persson PG, Karlén P, Bernell O, et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology. 1994;107(6):1675–1679
  70. Mellemkjaer L, Johansen C, Gridley G, et al. Crohn's disease and cancer risk (Denmark). Cancer Causes Control. 2000;11(2):145–150
  71. Fabia R, Levy MF, Testa G, et al. Colon carcinoma in patients undergoing liver transplantation. Am J Surg. 1998;176(3):265–269
  72. Okada SK, Siegel JN. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA. 2006;296(18):2201–2202author reply 2203–2204
  73. Bongartz T, Matteson EL, Montori VM, et al. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis-reply. November 8, 2006 JAMA. 2006;296(18):2203–2204
  74. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6(6):644–653
  75. Doumit J, Brzezinski A, Lashner B, et al. Comparison of safety and mortality of infliximab therapy to immunomodulator therapy in Crohn's disease: a cohort study. Am J Gastroenterol. 2005;100:S306
  76. Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut. 2006;55(2):228–233
  77. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(9):926–934
  78. Ho GT, Mowat A, Potts L, et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004–2008). Aliment Pharmacol Ther. 2009;29(5):527–534
  79. Karmiris K, Noman M, Schnitzler F, et al. Long-Term efficacy and safety of adalimumab treatment in a single-center cohort of Crohn's disease patients who failed to infliximab treatment. Gastroenterology. 2008;134(Suppl. 1):A658
  80. Travis SPL, Stange EF, Lémann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006;55(Suppl. 1):i16–i35
  81. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103(3):631–636
  82. Vermeire S, van Assche G, Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract Res Clin Gastroenterol. 2009;23(1):101–112
  83. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology. 2005;129(3):819–826
  84. Fiorino G, Allez M, Malesci A, et al. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29(9):921–927
  85. Sherlock ME, Walters TD, Zachos M, et al. Infliximab-induced psoriasis in pediatric crohn disease; experience of this paradoxical skin manifestation at a tertiary centre and a potential association with a variation in the IL-23r gene. DDW. 2009;2009:Poster Abstract W1133
  86. Fiorentino DF. The Yin and Yang of TNF-{alpha} inhibition. Arch Dermatol. 2007;143(2):233–236
  87. Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52(8):2513–2518
  88. Kary S, Worm M, Audring H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis. 2006;65(3):405–407
  89. Tobon GJ, Cañas C, Jaller J, et al. Serious liver disease induced by infliximab. Clin Rheumatol. 2007;26(4):578–581
  90. Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?. Arthritis Rheum. 2004;50(4):1040–1050
  91. Caspersen S, Elkjaer M, Riis L, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008;6(11):1212–1217quiz 1176
  92. Duricova D, Pedersen N, Elkjaer M, et al. Overall and cause-specific mortality in Crohn's disease: a meta-analysis of population-based studies. Inflamm Bowel Dis. 2010;16(2):347–353
  93. Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ. 2009;339:b2480
  94. Kinney T, Rawlins M, Kozarek R, et al. Immunomodulators and “On Demand” therapy with infliximab in Crohn's Disease: clinical experience with 400 infusions. Am J Gastroenterol. 2003;98(3):608–612
  95. Seiderer J, Göke B, Ochsenkühn T. Safety aspects of infliximab in inflammatory bowel disease patients. Digestion. 2004;70(1):3–9
  96. Orlando A, Colombo E, Kohn A, et al. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis. 2005;37(8):577–583
  97. Cohen RD. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis. 2001;7(S1):S17–S22
  98. Pacault V, Hritz FB, Gornet J, et al. Long term follow up of Crohn's disease patients treated with infliximab using an episodic strategy. Gastroenterology. 2006;130(4,Suppl. 2):A655
  99. Caviglia R, Ribolsi M, Rizzi M, et al. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J Gastroenterol. 2007;13(39):5238–5244
  100. de Vries HS, van Oijen MGH, de Jong DJ. Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands. Drug Saf. 2008;31(12):1135–1144

PII: S1521-6918(10)00003-X

doi: 10.1016/j.bpg.2010.01.002

Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 2 , Pages 167-182 , April 2010

Article Tools

* Image Usage & Resolution